PTC Therapeutics Q1 revenue $273M, raises FY product revenue guidance to $750-850M

PTC THERAPEUTICS, INC.

2026-Q1 EPS reported -$0.03 revenue$272,551,000

Q1 2026 total revenue $273M; product revenue $226M, up 47% YoY.
Net loss $2.8M vs net income $866.6M in Q1 2025 (prior year included non-recurring gain).
Sephience revenue $124.6M, up 36% QoQ; 1,244 patients on commercial therapy globally.
FY 2026 product revenue guidance raised to $750-850M; total revenue expected $1.08-1.18B.
Positive votoplam PIVOT-HD data; $50M milestone from Novartis triggered in Q2 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PTC THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue $273 million, net income Net loss was $2.8 million for the first quarter of 2026. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $273 million
Net income: Net loss was $2.8 million for the first quarter of 2026
Guidance: raised
Result: reported results

Exact text from the filing

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.